Your browser doesn't support javascript.
loading
Therapeutic Role of ELOVL in Neurological Diseases.
Siddiqui, Arif Jamal; Jahan, Sadaf; Chaturvedi, Swati; Siddiqui, Maqsood Ahmed; Alshahrani, Mohammed Merae; Abdelgadir, Abdelmushin; Hamadou, Walid Sabri; Saxena, Juhi; Sundararaj, Bharath K; Snoussi, Mejdi; Badraoui, Riadh; Adnan, Mohd.
Afiliación
  • Siddiqui AJ; Department of Biology, College of Science, University of Ha'il, P.O. Box 2440, Ha'il 81451, Saudi Arabia.
  • Jahan S; Molecular Diagnostics and Personalized Therapeutics Unit, University of Ha'il, P.O. Box 2440, Ha'il 81451, Saudi Arabia.
  • Chaturvedi S; Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Al Majmaah 11952, Saudi Arabia.
  • Siddiqui MA; Department of Pharmaceutics and Pharmacokinetics, Pre-Clinical North, Lab-106, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India.
  • Alshahrani MM; Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Kingdom of Saudi Arabia.
  • Abdelgadir A; Department of Clinical Laboratory Sciences, Faculty of Applied Medial Sciences, Najran University, P.O. Box 1988, Najran 61441, Saudi Arabia.
  • Hamadou WS; Department of Biology, College of Science, University of Ha'il, P.O. Box 2440, Ha'il 81451, Saudi Arabia.
  • Saxena J; Molecular Diagnostics and Personalized Therapeutics Unit, University of Ha'il, P.O. Box 2440, Ha'il 81451, Saudi Arabia.
  • Sundararaj BK; Department of Biology, College of Science, University of Ha'il, P.O. Box 2440, Ha'il 81451, Saudi Arabia.
  • Snoussi M; Molecular Diagnostics and Personalized Therapeutics Unit, University of Ha'il, P.O. Box 2440, Ha'il 81451, Saudi Arabia.
  • Badraoui R; Department of Biotechnology, University Institute of Biotechnology, Chandigarh University, Gharuan, NH-95, Chandigarh State Hwy, Ludhiana, Punjab 140413, India.
  • Adnan M; School of Dental Medicine, Department of Cellular and Molecular Biology, Boston University, Medical Campus Boston, Boston, Massachusetts 02215, United States.
ACS Omega ; 8(11): 9764-9774, 2023 Mar 21.
Article en En | MEDLINE | ID: mdl-36969404
Fatty acids play an important role in controlling the energy balance of mammals. De novo lipogenesis also generates a significant amount of lipids that are endogenously produced in addition to their ingestion. Fatty acid elongation beyond 16 carbons (palmitic acid), which can lead to the production of very long chain fatty acids (VLCFA), can be caused by the rate-limiting condensation process. Seven elongases, ELOVL1-7, have been identified in mammals and each has a unique substrate specificity. Researchers have recently developed a keen interest in the elongation of very long chain fatty acids protein 1 (ELOVL1) enzyme as a potential treatment for a variety of diseases. A number of neurological disorders directly or indirectly related to ELOVL1 involve the elongation of monounsaturated (C20:1 and C22:1) and saturated (C18:0-C26:0) acyl-CoAs. VLCFAs and ELOVL1 have a direct impact on the neurological disease. Other neurological symptoms such as ichthyotic keratoderma, spasticity, and hypomyelination have also been linked to the major enzyme (ELOVL1). Recently, ELOVL1 has also been heavily used to treat a number of diseases. The current review focuses on in-depth unique insights regarding the role of ELOVL1 as a therapeutic target and associated neurological disorders.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Omega Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ACS Omega Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Estados Unidos